SCHEDULE 13G/A: Armistice Capital and Steven Boyd Disclose 9.99% Stake in Catheter Precision, Inc.

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, reporting a shared beneficial ownership of 9.99% in Catheter Precision, Inc.'s common stock as of December 31, 2024.

Summary

• Armistice Capital, LLC and Steven Boyd (collectively, the "Reporting Persons") have filed an Amendment No. 2 to Schedule 13G.
• The filing reports their beneficial ownership in Catheter Precision, Inc. (the "Issuer"), a company with common stock, par value $0.0001 per share, and CUSIP 74933X609.
• As of December 31, 2024, the Reporting Persons collectively beneficially own 874,079 shares of Catheter Precision, Inc. common stock.
• This ownership represents 9.99% of the Issuer's outstanding common stock.
• Armistice Capital, LLC, a Delaware entity, acts as the investment manager for Armistice Capital Master Fund Ltd., which is the direct holder of the shares.
• Steven Boyd, a United States citizen, is the managing member of Armistice Capital, LLC.
• Both Armistice Capital, LLC and Steven Boyd possess shared voting power and shared dispositive power over all 874,079 beneficially owned shares.
• The Reporting Persons certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the Issuer.

Sentiment

Score: 5

Explanation: The document is a neutral, factual report of beneficial ownership, providing no explicit positive or negative sentiment regarding the issuer's performance or outlook.

Future Outlook

NA

Industry Context

NA

Key Dates

Keywords

Catheter Precision Inc., Armistice Capital LLC, Steven Boyd, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Investment Management, Institutional Investor